Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study

Yasuaki Nakagawa,Shogo Mukai,Shigeru Yamada,Masayuki Matsuoka,Eri Tarumi,Tadashi Hashimoto,Chieko Tamura,Atsushi Imaizumi,Jun Nishihira,Takashi Nakamura

doi:10.1007/s00776-014-0633-0

Abstract

Background We previously developed a surface-controlled water-dispersible form of curcumin and named it Theracurmin® (Theracurmin; Theravalues, Tokyo, Japan). The area under the blood concentration–time curve of Theracurmin in humans was 27-fold higher than that of curcumin powder. We determined the clinical effects of orally administered Theracurmin in patients with knee osteoarthritis during 8 weeks of treatment.Methods Fifty patients with knee osteoarthritis of Kellgren–Lawrence grade II or III and who were aged more than 40 years were enrolled in this randomized, double-blind, placebo-controlled, prospective clinical study. Placebo or Theracurmin containing 180 mg/day of curcumin was administered orally every day for 8 weeks. To monitor adverse events, blood biochemistry analyses were performed before and after 8 weeks of each intervention. The patients’ knee symptoms were evaluated at 0, 2, 4, 6, and 8 weeks by the Japanese Knee Osteoarthritis Measure, the knee pain visual analog scale (VAS), the knee scoring system of the Japanese Orthopedic Association, and the need for nonsteroidal anti-inflammatory drugs.Results At 8 weeks after treatment initiation, knee pain VAS scores were significantly lower in the Theracurmin group than in the placebo group, except in the patients with initial VAS scores of 0.15 or less. Theracurmin lowered the celecoxib dependence significantly more than placebo. No major side effects were observed with Theracurmin treatment.Conclusion Theracurmin shows modest potential for the treatment of human knee osteoarthritis.

Highlights

Osteoarthritis, referred to as degenerative joint disease, is a slow destructive process of the joints that affects millions of people worldwide
At 8 weeks after treatment initiation, knee pain visual analog scale (VAS) scores were significantly lower in the Theracurmin group than in the placebo group, except in the patients with initial VAS scores of 0.15 or less
Hip or knee osteoarthritis is a chronic condition that is usually treated with analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs), but these drugs sometimes cause serious gastrointestinal and cardiovascular adverse events, especially with long-term use [1, 2]

Summary

Introduction

Osteoarthritis, referred to as degenerative joint disease, is a slow destructive process of the joints that affects millions of people worldwide. Hip or knee osteoarthritis is a chronic condition that is usually treated with analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs), but these drugs sometimes cause serious gastrointestinal and cardiovascular adverse events, especially with long-term use [1, 2]. It has been suggested that an important mechanism of curcumin is inhibition of NF-kB activation [8], which is a key event in the chronic inflammatory process Given these findings, curcumin is expected to be effective for a range of diseases related to chronic inflammation, including cancer, cardiovascular disease, metabolic syndrome, Alzheimer disease, osteoarthritis, and other common diseases and aging conditions [3, 4, 9, 10]. The patients’ knee symptoms were evaluated at 0, 2, 4, 6, and 8 weeks by the Japanese Knee Osteoarthritis Measure, the knee pain visual analog scale (VAS), the knee scoring system of the Japanese Orthopedic Association, and the need for nonsteroidal anti-inflammatory drugs

Objectives

Methods

Results

Conclusion